Provided by Tiger Trade Technology Pte. Ltd.

Aktis Oncology

26.92
+0.93003.58%
Volume:253.45K
Turnover:6.69M
Market Cap:1.49B
PE:-22.19
High:27.03
Open:26.12
Low:25.71
Close:25.99
52wk High:34.19
52wk Low:14.72
Shares:55.28M
Float Shares:17.65M
Volume Ratio:1.03
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2134
EPS(LYR):-78.3394
ROE:-29.45%
ROA:-15.79%
PB:3.07
PE(LYR):-0.34

Loading ...

Analysts Conflicted on These Healthcare Names: Aktis Oncology, Inc. (AKTS) and Ramsay Health Care (OtherRMSYF)

TIPRANKS
·
Mar 31

Aktis Oncology Receives US FDA Approval for AKY-2519 Investigational New Drug Applications

MT Newswires Live
·
Mar 31

Aktis Oncology announces FDA clearance of AKY-25191 trial

TIPRANKS
·
Mar 31

Aktis Oncology FY25 net loss widens to $64M; R&D expenses climb to $68M

Reuters
·
Mar 31

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Benzinga_recent_news
·
Mar 09

Aktis Oncology Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 09

Aktis Oncology initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Mar 09

Aktis Oncology, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $30

THOMSON REUTERS
·
Mar 09

U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify

Reuters
·
Mar 09

Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors

TIPRANKS
·
Mar 05

Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target

TIPRANKS
·
Feb 25

Aktis Oncology to Present at Upcoming March Investor Conferences

GlobeNewswire
·
Feb 25

BRIEF-Aktis Oncology Receives U.S. FDA Fast Track Designation For Aky-1189

Reuters
·
Feb 24

Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189

TIPRANKS
·
Feb 24

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

GlobeNewswire
·
Feb 24

Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO

Reuters
·
Feb 23